Insider Selling: Phreesia, Inc. (NYSE:PHR) CFO Sells $173,360.84 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 5,771 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $30.04, for a total transaction of $173,360.84. Following the completion of the transaction, the chief financial officer now owns 105,514 shares in the company, valued at $3,169,640.56. This trade represents a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total transaction of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The shares were sold at an average price of $27.48, for a total transaction of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The shares were sold at an average price of $27.31, for a total transaction of $159,135.37.
• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total transaction of $85,018.95.

Phreesia Stock Down 0.9 %

PHR stock opened at $28.20 on Friday. The stock has a market capitalization of $1.64 billion, a P/E ratio of -19.18 and a beta of 0.96. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The firm has a 50-day moving average price of $27.29 and a 200-day moving average price of $23.84.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. During the same quarter in the prior year, the firm posted ($0.58) earnings per share. The firm’s revenue was up 16.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PHR shares. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research report on Friday, January 10th. Piper Sandler reaffirmed an “overweight” rating and set a $33.00 price objective (up previously from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Citigroup upped their price objective on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Finally, KeyCorp upped their price objective on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $31.15.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. increased its stake in shares of Phreesia by 0.9% in the fourth quarter. Invesco Ltd. now owns 40,249 shares of the company’s stock valued at $1,013,000 after buying an additional 357 shares during the period. NewEdge Advisors LLC increased its stake in shares of Phreesia by 12.1% in the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company’s stock valued at $107,000 after buying an additional 459 shares during the period. Johnson Financial Group Inc. increased its stake in shares of Phreesia by 381.3% in the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after buying an additional 896 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Phreesia by 3.3% in the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after buying an additional 905 shares during the period. Finally, MetLife Investment Management LLC increased its stake in shares of Phreesia by 3.8% in the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock valued at $701,000 after buying an additional 1,120 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.